George MD, et al. - In this retrospective cohort study, using U.S. Medicare and Truven MarketScan administrative data from 2006 to 2015, researchers examined the association of holding abatacept infusions with a lower risk of adverse postoperative outcomes. They recorded 175 hospitalized infections, 115 non-urinary hospitalized infections, 39 prosthetic joint infections (PJI), and 114 30-day readmissions after 1939 surgeries among 1780 cases. No significant variations in outcomes with abatacept stop timing < 4 weeks (one dosing interval) vs 4-8 weeks [hospitalized infection, non-urinary hospitalized infection, PJI, 30-day readmission] or vs ≥8 weeks were observed. They found a relation of glucocorticoid use > 7.5mg/day with a greater risk of hospitalized infection and non-urinary hospitalized infection.